High Intensity Focused Ultrasound versus Brachytherapy for the Treatment of Localized Prostate Cancer: A Matched-Pair Analysis

Table 4

Comparison of early and long term postoperative complications according to the therapeutic approach.

	BT	HIFU	Maxis; Ablatherm	Ablatherm integrated; imaging	p value; (BT versus HIFU)	p value; (BT versus Maxis)	p value; (BT versus integrated imaging)
(A) Early
=	59	90	39	31	—	—	—
Acute urinary retention	4 (6.8%)	16 (22.9%)	12 (30.8%)	4 (12.9%)	0.02	<0.01	0.44
Urinary tract infection	5 (8.5%)	15 (21.4%)	12 (30.8%)	3 (9.7%)	0.07	<0.01	0.86
LUTS	25 (42.4%)	28 (40.0%)	17 (43.6%)	11 (35.5%)	0.93	1	0.68
(i) Storage	19 (32.2%)	5 (7.2%)	3 (7.7%)	2 (6.4%)	<0.01	<0.01	0.01
(ii) Voiding	6 (10.2%)	23 (32.8%)	14 (35.9%)	9 (29.1%)	<0.01	<0.01	0.04
Gastrointestinal toxicity	2 (3.4%)	1 (1.4%)	1 (2.6%)	0 (0.0%)	0.59	1	0.78
(B) Long term
=	53	69	39	30	—	—	—
LUTS	14 (26.4%)	19 (27.5%)	12 (30.8%)	7 (23.3%)	1	0.82	0.96
(i) Storage	10 (18.9%)	7 (10.1%)	4 (10.3%)	3 (10.0%)	0.26	0.30	0.36
(ii) Voiding	4 (7.5%)	12 (17.4%)	8 (20.5%)	4 (13.3%)	0.18	0.18	0.45
Urethral stricture	2 (3.8%)	17 (24.6%)	12 (30.8%)	5 (16.7%)	<0.01	<0.01	0.09
Rectourethral fistula	1 (1.9%)	1 (1.4%)	1 (2.6%)	0 (0.0%)	1	1	1
Chronic pelvic pain	0 (0.0%)	3 (4.3%)	3 (7.7%)	0 (0.0%)	0.34	0.08	1
Urinary incontinence	2 (3.8%)	5 (7.2%)	3 (7.7%)	2 (6.7%)	0.44	0.72	0.62

Brachytherapy, high intensity focused ultrasound, and lower urinary tract symptoms.